Based on the key indicators related to Aurinia Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Aurinia Pharmaceuticals is not in a good financial situation at this time. It has a very high odds of going through financial crisis in December. As of now, Aurinia Pharmaceuticals' Total Current Liabilities is increasing as compared to previous years. The Aurinia Pharmaceuticals' current Total Stockholder Equity is estimated to increase to about 396.9 M, while Retained Earnings are forecasted to increase to (895.2 M). Key indicators impacting Aurinia Pharmaceuticals' financial strength include:
Investors should never underestimate Aurinia Pharmaceuticals' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Aurinia Pharmaceuticals' cash flow, debt, and profitability to make informed and accurate decisions about investing in Aurinia Pharmaceuticals.
Net Income
(74.12 Million)
Aurinia
Select Account or Indicator
Market Cap
Enterprise Value
Price To Sales Ratio
Ptb Ratio
Days Sales Outstanding
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Average Payables
Stock Based Compensation To Revenue
Capex To Depreciation
Pb Ratio
Ev To Sales
Free Cash Flow Per Share
Roic
Inventory Turnover
Net Income Per Share
Days Of Inventory On Hand
Payables Turnover
Sales General And Administrative To Revenue
Average Inventory
Research And Ddevelopement To Revenue
Capex To Revenue
Cash Per Share
Pocfratio
Interest Coverage
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Intangibles To Total Assets
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Receivables Turnover
Graham Number
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Average Receivables
Revenue Per Share
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Short Term Coverage Ratios
Price Earnings Ratio
Operating Cycle
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Long Term Debt To Capitalization
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Ebit Per Revenue
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Cash Conversion Cycle
Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding
Days Of Sales Outstanding
Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Fixed Asset Turnover
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Price Sales Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Gross Profit Margin
Price Fair Value
Return On Equity
Change In Cash
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Other Cashflows From Financing Activities
Depreciation
Other Non Cash Items
Capital Expenditures
Total Cash From Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Change To Inventory
Sale Purchase Of Stock
Investments
Net Borrowings
Total Cashflows From Investing Activities
Change To Account Receivables
Change To Operating Activities
Other Cashflows From Investing Activities
Change To Netincome
Change To Liabilities
Stock Based Compensation
Total Assets
Short Long Term Debt Total
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Property Plant And Equipment Net
Net Debt
Retained Earnings
Accounts Payable
Non Current Assets Total
Net Receivables
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Non Current Liabilities Total
Inventory
Other Current Assets
Other Stockholder Equity
Total Liab
Property Plant And Equipment Gross
Total Current Assets
Accumulated Other Comprehensive Income
Short Term Debt
Intangible Assets
Current Deferred Revenue
Cash
Non Currrent Assets Other
Cash And Short Term Investments
Other Liab
Net Tangible Assets
Other Assets
Long Term Debt
Common Stock Total Equity
Retained Earnings Total Equity
Short Term Investments
Deferred Long Term Liab
Common Stock
Property Plant Equipment
Capital Surpluse
Non Current Liabilities Other
Net Invested Capital
Net Working Capital
Capital Stock
Capital Lease Obligations
Depreciation And Amortization
Interest Expense
Selling General Administrative
Total Revenue
Gross Profit
Other Operating Expenses
Operating Income
Ebit
Research Development
Ebitda
Cost Of Revenue
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Income Tax Expense
Net Income From Continuing Ops
Net Income Applicable To Common Shares
Interest Income
Net Interest Income
Reconciled Depreciation
Tax Provision
Probability Of Bankruptcy
Understanding current and past Aurinia Pharmaceuticals Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Aurinia Pharmaceuticals' financial statements are interrelated, with each one affecting the others. For example, an increase in Aurinia Pharmaceuticals' assets may result in an increase in income on the income statement.
Aurinia Pharmaceuticals competes with Viking Therapeutics, Axsome Therapeutics, Madrigal Pharmaceuticals, Seres Therapeutics, and Exelixis. Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. Aurinia Pharm operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 300 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Comparative valuation techniques use various fundamental indicators to help in determining Aurinia Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Aurinia Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Aurinia Pharmaceuticals competition to find correlations between indicators driving Aurinia Pharmaceuticals's intrinsic value. More Info.
Aurinia Pharmaceuticals is rated third in return on equity category among its peers. It is rated fourth in return on asset category among its peers . As of now, Aurinia Pharmaceuticals' Return On Equity is decreasing as compared to previous years. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Aurinia Pharmaceuticals' earnings, one of the primary drivers of an investment's value.
Aurinia Pharmaceuticals Systematic Risk
Aurinia Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Aurinia Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was ten with a total number of output elements of fifty-one. The Beta measures systematic risk based on how returns on Aurinia Pharmaceuticals correlated with the market. If Beta is less than 0 Aurinia Pharmaceuticals generally moves in the opposite direction as compared to the market. If Aurinia Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Aurinia Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Aurinia Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Aurinia Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Aurinia Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Aurinia Pharmaceuticals' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Aurinia Pharmaceuticals growth as a starting point in their analysis.
Aurinia Pharmaceuticals November 30, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Aurinia Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Aurinia Pharmaceuticals. We use our internally-developed statistical techniques to arrive at the intrinsic value of Aurinia Pharmaceuticals based on widely used predictive technical indicators. In general, we focus on analyzing Aurinia Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Aurinia Pharmaceuticals's daily price indicators and compare them against related drivers.
When running Aurinia Pharmaceuticals' price analysis, check to measure Aurinia Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aurinia Pharmaceuticals is operating at the current time. Most of Aurinia Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Aurinia Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aurinia Pharmaceuticals' price. Additionally, you may evaluate how the addition of Aurinia Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.